Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

NCT02452554 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

NETWORK

Sponsor class

Conditions

Pleuropulmonary Blastoma
Recurrent Malignant Peripheral Nerve Sheath Tumor
Recurrent Neuroblastoma
Recurrent Rhabdomyosarcoma
Recurrent Synovial Sarcoma
Wilms Tumor

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Lorvotuzumab Mertansine
OTHER: Pharmacological Study

Sponsor

Children's Oncology Group

Collaborators

[object Object]